Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome

Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026. Check out my analysis of RGNX stock.